我国是原发性肝癌（Primary carcinoma of the liver）的高发地区,每年约11万人死于肝癌,占全世界肝癌死亡人数的50%[1]。原发性肝癌较易发生肺部转移,转移率可高达20%以上,尸检发现率可高达40%～73%[2]。对于转移性肝癌患者可进行全身...我国是原发性肝癌（Primary carcinoma of the liver）的高发地区,每年约11万人死于肝癌,占全世界肝癌死亡人数的50%[1]。原发性肝癌较易发生肺部转移,转移率可高达20%以上,尸检发现率可高达40%～73%[2]。对于转移性肝癌患者可进行全身化疗来作为姑息治疗，近年来吉西他滨联合奥沙利铂（GEMOX方案）治疗晚期原发性肝癌有大量报道。我们自2008—05—2010—03试以GEMOX方案联合中药治疗了6例原发性肝癌并肺转移患者，取得了令人满意的效果。现报道如下。展开更多
We report the successful treatment of multiple lung metastases after hepatic resection for hepatocellular carcinoma (HCC) with combined docetaxel, cisplatin (CDDP), and enteric-coated tegafur/uracil (UFT-E). A 68-year...We report the successful treatment of multiple lung metastases after hepatic resection for hepatocellular carcinoma (HCC) with combined docetaxel, cisplatin (CDDP), and enteric-coated tegafur/uracil (UFT-E). A 68-year-old man was diagnosed with multiple lung metastases of HCC 7 mo after partial hepatectomy for HCC. Oral UFT-E was given daily and docetaxel and CDDP were given intra-arterially (administered just before the bronchial arteries) every 2 wk via a subcutaneous injection port. One month after starting chemotherapy, levels of tumor marker, protein induced by vitamin K absence(PIVKA--), decreased rapidly,and after a further month, chest X-ray and computed tomography revealed the complete disappearance of multiple liver metastases. Two years after the combined chemotherapy, HCC recurred in the liver and was treated but no pulmonary recurrence occurred. In the absence of a standardized highly effective therapy, this combined chemotherapy with docetaxel, CDDP and UFT-E may be an attractive option for multiple lung metastases of HCC.展开更多
文摘我国是原发性肝癌（Primary carcinoma of the liver）的高发地区,每年约11万人死于肝癌,占全世界肝癌死亡人数的50%[1]。原发性肝癌较易发生肺部转移,转移率可高达20%以上,尸检发现率可高达40%～73%[2]。对于转移性肝癌患者可进行全身化疗来作为姑息治疗，近年来吉西他滨联合奥沙利铂（GEMOX方案）治疗晚期原发性肝癌有大量报道。我们自2008—05—2010—03试以GEMOX方案联合中药治疗了6例原发性肝癌并肺转移患者，取得了令人满意的效果。现报道如下。
文摘We report the successful treatment of multiple lung metastases after hepatic resection for hepatocellular carcinoma (HCC) with combined docetaxel, cisplatin (CDDP), and enteric-coated tegafur/uracil (UFT-E). A 68-year-old man was diagnosed with multiple lung metastases of HCC 7 mo after partial hepatectomy for HCC. Oral UFT-E was given daily and docetaxel and CDDP were given intra-arterially (administered just before the bronchial arteries) every 2 wk via a subcutaneous injection port. One month after starting chemotherapy, levels of tumor marker, protein induced by vitamin K absence(PIVKA--), decreased rapidly,and after a further month, chest X-ray and computed tomography revealed the complete disappearance of multiple liver metastases. Two years after the combined chemotherapy, HCC recurred in the liver and was treated but no pulmonary recurrence occurred. In the absence of a standardized highly effective therapy, this combined chemotherapy with docetaxel, CDDP and UFT-E may be an attractive option for multiple lung metastases of HCC.
